Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762404
Reconstruction of First Web Space After Trauma and BurnSohag UniversityNot Yet RecruitingNot Applicable
NCT07762404Not Yet Recruiting
Not Applicable
Reconstruction of First Web Space After Trauma and BurnSohag University
NCT07763769
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)Medhub Ltd.Completed
NCT07763769Completed
—
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional...Medhub Ltd.
NCT07762508
A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low-Performance or High-Comorbidity AML Patients in CR1The First Affiliated Hospital of Soochow UniversityNot Yet RecruitingNot Applicable
NCT07762508Not Yet Recruiting
Not Applicable
A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSCT for Low...The First Affiliated Hosp...
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDChifeng Municipal HospitalRecruiting
NCT07762872Recruiting
—
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in...Chifeng Municipal Hospita...
NCT07762690
Mechanism-Based Cervical Rehabilitation for Chronic MigraineBeni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07762690Not Yet Recruiting
Not Applicable
Mechanism-Based Cervical Rehabilitation for Chronic MigraineBeni-Suef University
NCT07762898
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and FrailtyGansu University of Chinese MedicineNot Yet RecruitingNot Applicable
NCT07762898Not Yet Recruiting
Not Applicable
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and...Gansu University of Chine...
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07763197
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)Natera, Inc.Recruiting
NCT07763197Recruiting
—
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle...Natera, Inc.
NCT07763236
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituitary AdenomasTomislav FelbabićCompletedNot Applicable
NCT07763236Completed
Not Applicable
Indocyanine Green Fluorescence in Endoscopic Resection of Non-Functioning Pituit...Tomislav Felbabić
NCT07764237
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsModernaTX, Inc.Not Yet RecruitingPhase 1
NCT07764237Not Yet Recruiting
Phase 1
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (...ModernaTX, Inc.
NCT07764094
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery DiseaseNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764094Recruiting
—
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery...Nanjing First Hospital, N...
NCT07762599
Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Periodontitis: A Randomized Controlled TrialAll India Institute of Medical SciencesNot Yet RecruitingNot Applicable
NCT07762599Not Yet Recruiting
Not Applicable
Silver Nanoparticle-Reinforced Double Antibiotic Paste in Symptomatic Apical Per...All India Institute of Me...
NCT07762066
Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression Among Older Gay and Bisexual MenFenway Community HealthRecruitingNot Applicable
NCT07762066Recruiting
Not Applicable
Bridge to Belonging: Peer Led Intervention to Reduce Loneliness and Depression A...Fenway Community Health
NCT07763444
The Impact of Experiential Simulation on Nursing StudentsNecmettin Erbakan UniversityCompletedNot Applicable
NCT07763444Completed
Not Applicable
The Impact of Experiential Simulation on Nursing StudentsNecmettin Erbakan Univers...
NCT07763158
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent Pain in Patients With Severe Knee OsteoarthritisKing Abdullah International Medical Research CenterRecruitingNot Applicable
NCT07763158Recruiting
Not Applicable
Evaluating the Role of Genicular Artery Embolization in Treatment of Persistent...King Abdullah Internation...
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07762729
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up StudyChildren's Hospital of Fudan UniversityEnrolling By Invitation
NCT07762729Enrolling By Invitation
—
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up...Children's Hospital of Fu...
NCT07763821
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.Assiut UniversityNot Yet Recruiting
NCT07763821Not Yet Recruiting
—
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephrit...Assiut University
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07762092
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai LimitedNot Yet Recruiting
NCT07762092Not Yet Recruiting
—
A Post Authorization Registry Study of Participants Treated With LEQEMBIEisai Limited
Result Breakdown
Not yet recruiting10 (50%)
Recruiting6 (30%)
Completed3 (15%)
Enrolling by invitation1 (5%)
not_applicable9 (45%)
Not Specified8 (40%)
Phase 12 (10%)
Phase 21 (5%)